There were no significant differences in IL-17F among treatment naïve patients (mean ± SD: 14.65 ± 10.57 pg/ml; median: 11.93 pg/ml; range: 1.73–40.84 pg/ml) compared to those on IBD therapy (mean ± SD: 21.90 ± 28.75 pg/ml; median: 16.89 pg/ml; range: 0.09–189.84 pg/ml) (p = 0.09). Here, IL17F is linked to inflammatory bowel disease.